This paper is only available as a PDF. To read, Please Download here.
Abstract
The development of oral lesions in erythema multiforme exudativum has been divided
into five distinct stages—macular, bullous, sloughing, pseudo-membranous, and healing.
Each stage is clinically and histologically different and is dependent upon the degree
of lesion development. Evidence has been presented to suggest an intraepithelial rather
than an intradermal origin of the oral bulla of erythema multiforme exudativum. Each
stage has been illustrated by clinical photographs and demonstrated microscopically
to show the progress of the lesions from initial eruption to final healing. Knowledge
of this progression should aid both in diagnosis and in the prediction of the approximate
length of time the patient will have the disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- “Stevens-Johnson Syndrome”; Report of a Case Associated With Culturally Proven Mycoplasma Infection.J. A. M. A. 1967; 199: 504-506
- Erythema Multiforme Exudativum (Hebra): A Clinical Entity Associated With Systemic Features.Ann. Int. Med. 1940; 14: 449
- Dermatology.in: ed. 1. W. B Saunders Company, Philadelphia1956: 768
- Oral Lesions of Erythema Multiforme.Arch. Dermat. 1965; 92: 495-500
Article info
Footnotes
☆The opinions expressed herein are those of the authors and are not to be construed as expressing official United States Air Force or Navy policy or opinion.
Identification
Copyright
© 1967 Published by Elsevier Inc.